Global CDMO scale Vetter Pharma operates as a leading global contract development and manufacturing organization with state-of-the-art aseptic injectable production facilities in Europe and the United States, signaling strong capacity to take on larger supplier partnerships and multi-region supply contracts.

Expansion momentum Significant recent investments and expansion plans include a 50,000 sqm manufacturing site, laboratories, and warehouses, plus mobile cold chain solutions. This signals increased capabilities for complex biologics or temperature-sensitive products and potential for new capacity deals.

Cold chain expertise Introduction of mobile freezer solutions and robust cold chain infrastructure positions Vetter as a preferred partner for temperature-sensitive biologics and high-value therapies requiring reliable distribution and compliant handling.

Strategic partnerships Recent collaborations with MoonLake Immunotherapeutics and ongoing relationships with banks and law firms for refinancing indicate a strong value proposition to financially and operationally support long-term manufacturing programs, inviting co-development and supply agreements.

Awarded reliability Multiple Best Managed Company awards and recognized leadership in the CDMO space reinforce credibility with potential customers seeking dependable, well-governed manufacturing partners for complex injectable medicines and oncology therapies.